Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo

G Karsenty, J Rocha, S Chevalier, E Scarlata… - The …, 2009 - Wiley Online Library
… Gilles Karsenty,1,2,3 Joice Rocha,4 Simone Chevalier,4 Eleonora Scarlata,4 Claudia Andrieu,3
Fatima Z. Zouanat,4 … Gilles Karsenty and Joice Rocha contributed equally to this study. …

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

…, R Nassim, S Chevalier, J Rocha… - Cancer biology & …, 2009 - Taylor & Francis
We examined whether mTOR inhibition by RAD001 (Everolimus) could be therapeutically
efficacious in the treatment of bladder cancer. RAD001 markedly inhibited proliferation of nine …

The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth

A Zoubeidi, J Rocha, FZ Zouanat, L Hamel… - Molecular Cancer …, 2009 - AACR
Androgen withdrawal is the most effective form of systemic therapy for men with advanced
prostate cancer. Unfortunately, androgen-independent progression is inevitable, and the …

[HTML][HTML] A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer

…, R Nassim, S Chevalier, K Szymanski, J Rocha… - PLoS …, 2013 - journals.plos.org
Background Two signalling molecules that are attractive for targeted therapy are the epidermal
growth factor receptor (EGFR) and the peroxisome proliferator-activated receptor gamma …

Electrochemical red-ox therapy of prostate cancer in nude mice

FL Cury, B Bhindi, J Rocha, E Scarlata, K El Jurdi… - …, 2015 - Elsevier
Minimally invasive therapies are increasingly in demand for organ-confined prostate tumors.
Electrochemical therapy (EChT) is attractive, as it relies on locally-induced reduction–…

The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer

J Rocha, FZ Zouanat, A Zoubeidi, L Hamel… - Molecular and cellular …, 2013 - Elsevier
Castrate-resistant prostate cancer (CRPC) is invariably lethal and still poorly understood. IL-6/pSTAT3
appears critical as elevated IL-6 and pSTAT3 correlate with CRPC and poor …

Refining the orthotopic dog prostate cancer (DPC)‐1 model to better bridge the gap between rodents and men

M Anidjar, E Scarlata, FL Cury, J Rocha, L Hamel… - The …, 2012 - Wiley Online Library
BACKGROUND Rodent models are often suboptimal for translational research on human
prostate cancer (PCa). To better fill the gap with human, we refined the previously described …

Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a …

J Rocha, AG Aprikian, M Vanhuyse, FL Cury… - … Open Access Journal, 2017 - cmajopen.ca
Background: Abiraterone acetate was introduced in Quebec in 2012 for the treatment of
metastatic castration-resistant prostate cancer (mCRPC) in patients who had received …

Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model

…, E Scarlata, E El-Zayat, L Hamel, J Rocha… - The Journal of …, 2013 - auajournals.org
Purpose : Vascular targeted photodynamic therapy with WST11 (TOOKAD® Soluble) is in
phase III clinical trials of an interstitial transperineal approach for focal therapy of prostate …

Análise dos avanços na construção civil utilizando métodos de capacitação de mão de obra no estado do Amazonas: Analysis of advances in civil construction using …

JA Rocha, AE Sanches… - Brazilian Journal …, 2022 - ojs.brazilianjournals.com.br
A engenharia civil e os avanços tecnológicos que moldam o setor construtivo impactam no
desenvolvimento da sociedade constantemente. Entretanto, a cada surgimento de uma …